News & Videos - SEQUANA

Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent ......

Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent ......

Sequana Medical is a Belgian commercial-stage medical device company that uses its proprietary alfapump and Direct Sodium Removal (DSR) technologies to ......

PRESS RELEASE 19 MARCH 2020 07:00 CET REGULATED INFORMATION Continued strong progress in U.S. NASH-related and global heart failure programmes Successfully raised €19 million in Q1 2020 extending cash runway into H1 2021 Conference call with live webcast presentation today at 14:00 CET / 09:00 ET Ghent, BELGIUM – 19 March 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”) , an innovator in the management of fluid overload in liver disease, malignant ascites and heart...

Ghent, BELGIUM – 12 March 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) , an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, will announce its results for the full year ended 31 December 2019 and outlook for 2020 on Thursday 19 March 2020. The management team will host a conference call with a live webcast presentation at 14.00 CET / 09:00 ET on the day of the results. The webcast can be accessed by registering via the investors...

REGULATED INFORMATION Ghent, BELGIUM – 21 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "...

REGULATED INFORMATION Ghent, BELGIUM – 3 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the " Belgian...

PRESS RELEASE REGULATED INFORMATION 29 January 2020, 07:00 CET Ghent, Belgium, 29 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding...

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 22 January 2020, 21:30 CET Ghent, Belgium , 22 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), an innovator in the management of fluid overload in liver disease,...

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 22 January 2020, 15:50 CET Ghent, Belgium , 22 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), an innovator in the management of fluid overload in liver disease,...

Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for treatment of volume overload due to heart failure Ghent, BELGIUM – 10 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) , an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the results of the pre-clinical and...

The study aims to: Evaluate the safety of alfa pump DSR in patients with heart failure Assess the feasibility of alfa pump DSR to remove excess sodium and fluid from the body Explore the potential impact of DSR therapy to restore response to diuretics Ghent, BELGIUM – 7 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) , an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled...

Regulated information Continued strong progress since IPO in February 2019: Commenced POSEIDON pivotal study to support approval of the alfa pump® in the U.S. & Canada Achieved clinical proof-of-concept of Direct Sodium Removal (DSR), potential breakthrough therapy for volume overload due to heart failure Conference call with live webcast presentation today at 14:00 CET / 08:00 ET. Ghent, BELGIUM – 25 September 2019 – Sequana Medical NV (Euronext Brussels: SEQUA) , an innovator in the...

Study aims to support the approval of the alfa pump in U.S. and Canada Results anticipated by mid-2021 U.S. launch of the alfa pump planned for H1 2022 Ghent, BELGIUM – 25 September 2019 – Sequana Medical NV (Euronext Brussels: SEQUA) , innovators in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the North American pivotal study (POSEIDON) of the alfa pump for the treatment of recurrent...

Dr. Butler, Dr. Costanzo, Dr. Tang and Dr. Testani to advise on alfa pump® DSR development Ghent, BELGIUM – 19 September 2019 – Sequana Medical NV (Euronext Brussels: SEQUA) , innovators in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointments of Dr. Javed Butler, Dr. Maria Rosa Costanzo, Dr. Wilson Tang and Dr. Jeffrey Testani as the Company’s Heart Failure Scientific Advisors. The Sequana Medical management team will...

Results and conference call with live webcast will take place on 25 September 2019 Ghent, BELGIUM – 14 August 2019 – Sequana Medical NV (Euronext Brussels: SEQUA) , innovators in the management of fluid overload in liver disease, malignant ascites and heart failure, announces today that it has changed the date of its Half Year 2019 Results to Wednesday, 25 September 2019. The management team will host a conference call with a live webcast presentation at 14.00 CEST / 08.00 ET on the day of...

Communiqué de presse Boulogne-Billancourt, le 18 juin 2019 Par décision d'Euronext du 17 juin 2019, les actions Sequana seront radiées d'Euronext Paris à compter du 19 juin 2019 à la suite de la liquidation judiciaire de la société prononcée par le tribunal de commerce de Nanterre. Information réglementée Informations privilégiées : - Autres communiqués Communiqué intégral et original au format PDF :...

REGULATED INFORMATION – INSIDE INFORMATION alfa pump pivotal study for treatment of recurrent or refractory ascites due to liver cirrhosis Optimised clinical trial design of up to 50 patients implanted with alfa pump in study cohort and shorter follow-up time for primary endpoint analysis Planned U.S. launch of alfa pump moved forward to H1 2022 Proposed rule of Centers for Medicare and Medicaid Services (CMS) on payment system for breakthrough devices is a positive development for the alfa...

REGULATED INFORMATION – INSIDE INFORMATION First-in-human single dose DSR study meets primary and secondary endpoints Direct Sodium Removal (DSR) was safe & well-tolerated Substantially higher sodium removal with DSR vs standard Peritoneal Dialysis (PD) solution Consistent results between treated patients First clinical study of repeated dose DSR with alfa pump ® (alfa pump DSR) planned to commence in H2 2019 Sequana Medical management and Dr. Jeffrey Testani to host a conference call and...

Experienced MedTech Executive Jason Hannon appointed as Non-Executive Director Ghent, BELGIUM – 23 May 2019 (18:00 CEST) – Sequana Medical NV (Euronext Brussels: SEQUA) , a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today that the proposed resolutions presented at its Annual General Meeting of Shareholders (AGM) were...